News

07-16-2015

Avineuro Completed Phase II Clinical Study Of AVN-211, A Selective 5-HT6 Receptor Antagonist Avineuro LLC announced completion of phase II pilot clinical study of AVN-211, a proprietary orally-bioavailable molecule of a 5-HT6 receptor antagonist. In a multicenter double-blind randomized placebo-controlled pilot study of efficacy and safety of AVN-211 for amplifying the effects of antipsychotic drugs […]

View Full Article
07-1-2015

July 1, 2015. Avineuro LLC announced completion of phase II pilot clinical study of AVN-211, a proprietary orally-bioavailable molecule of a 5-HT6 receptor antagonist. In a multicenter double-blind randomized placebo-controlled pilot study of efficacy and safety of AVN-211 for amplifying the effects of antipsychotic drugs in patients with schizophrenia in a condition of incomplete remission […]

View Full Article
07-15-2013

San Diego, CA – July 15th, 2013 – Avineuro Pharmaceuticals, Inc. announced today an initiation of Phase 2b clinical studies of AVN-211, the best in-class, selective small molecule antagonist of 5-HT6 receptor for treatment of Schizophrenia. Earlier Avineuro Pharmaceuticals, Inc. reported positive top-line results from a Phase 2a clinical trial in schizophrenia patients stabilized on […]

View Full Article
02-21-2011

San Diego, CA – February 21st, 20011 – Avineuro Pharmaceuticals, Inc. reported today positive top-line results from a Phase 2a clinical proof of concept trial to assess AVN-211 as an augmentation therapy to improve cognition in schizophrenia patients. In a double blind trial in 50 patients stabilized on an atypical antipsychotic therapy, AVN-211 met the […]

View Full Article
03-1-2010

San Diego, CA – March 1st, 2010 – Avineuro Pharmaceuticals, Inc. reported today clinical Phase I results on AVN-322, a potent and selective small molecule antagonist of 5-HT6 receptor for treatment of Alzheimer’s disease. AVN-322 was well tolerated in a wide range of doses and no adverse events were observed. Avineuro Pharmaceuticals, Inc. plans to […]

View Full Article

Events

02-20-2010

Avineuro Pharmaceuticals, Inc. will be participating in Alzheimer’s Association International Conference on Alzheimer’s Disease 2010 (ICAD)

View Full Article
02-20-2010

Avineuro Pharmaceuticals, Inc. will be presenting at ABIO-Europe 2010 conference in Barcelona, Spain

View Full Article
11-2-2009

Avineuro Pharmaceuticals, Inc. participates in ABIO-Europe 2009 conference in Vienna on November 2-4, 2009.

View Full Article
10-10-2009

Avineuro Pharmaceuticals, Inc. participates in BioNetwork West 2009 conference in Laguna Niguel, CA on October 5-7, 2009.

View Full Article
10-5-2009

Avineuro Pharmaceuticals, Inc. participates in BioNetwork West 2009 conference in Laguna Niguel, CA on October 5-7, 2009.

View Full Article
More...
More...